TELO Telomir Pharmaceuticals, Inc.

TELO financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1971532 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 6, 2026 Data checked: Nov 10, 2026
Showing 3 of 4 annual and 0 of 14 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity Type
Operating
Public Float
$18.10M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
FL
Fiscal Year End
December (1231)
Phone
786-396-6723
EIN
872606031
Headquarters
MIAMI, FL, 33131
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
-
Net Income
$-5.48M
Total Assets
$4.64M
Total Equity
$4.40M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-124.4%
Return on Assets
-118%
Current Ratio
19.6x
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Telomir Pharmaceuticals, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense $2.44M $2.24M $1.57M
SG&A Expense $8.10M $9.64M $600.19K
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $1.64M
Interest Income $125.64K $48.00K -
Net Income $-10.41M $-16.53M $-13.07M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.33 $-0.56 $0.48
Diluted Shares 31.65M 29.54M 27.30M
Balance Sheet
ASSETS
Other Current Assets $54.69K $57.87K $713
Current Assets $7.34M $1.32M $435.23K
Noncurrent Assets $0 $0 $4.34M
Total Assets $7.34M $1.32M $4.77M
LIABILITIES
Accounts Payable $536.77K $587.54K $707.19K
Other Current Liabilities $318.23K $93.43K $527.38K
Current Liabilities $1.43M $680.97K $1.34M
Other Noncurrent Liabilities - - $527.38K
Noncurrent Liabilities $0 $0 $0
Total Liabilities $1.43M $680.97K $1.34M
EQUITY
Additional Paid-in Capital $46.92M $31.24M $17.50M
Retained Earnings $-41.01M $-30.60M $-14.06M
Total Equity $5.91M $643.04K $3.44M
Total Liabilities & Equity $7.34M $1.32M $4.77M
SUPPLEMENTAL
Shares Outstanding 34.38M 29.76M 28.61M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-3.69M $-5.07M $-3.86M
Capital Expenditures - - -
Cash from Investing $0 $0 $0
Cash from Financing $9.71M $6.34M $3.86M
Free Cash Flow - - -
Beginning Cash (CFS) $1.27M $1.23K $1.42K
Net Change in Cash $6.02M $1.26M $-188
Effect of FX on Cash - - -
Calculated Ending Cash $7.29M $1.27M $1.23K
Cash per BS - - -
Cash scope difference (CFS − BS) - - -
Cash per CFS $7.29M $1.27M $1.23K

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. profitable?

No. Telomir Pharmaceuticals, Inc. reported $-5.48M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.